The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of pan-PI3K and HER2 blockade on antitumor activity in preclinical models of breast cancer resistance to trastuzumab therapy.
Pradip De
No relevant relationships to disclose
Yuliang Sun
No relevant relationships to disclose
Lori Friedman
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Nandini Dey
No relevant relationships to disclose
Brian Leyland-Jones
No relevant relationships to disclose